drugset / Trial / NCT02012062
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
Phase 3
Completed
160 enrolled
Fudan University
Fujian Province Tumor Hospital · collabThe First Affiliated Hospital of Xiamen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally advanced NPC. Three hundreds and twenty patients will be recruited into this study.
Timeline
- Start
- 2012-07
- Primary completion
- 2016-03
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2500 mg/m2 | — |